Rethinking primary CVD prevention in type 2 diabetes today
Patients with type 2 diabetes mortality is driven primarily by CV disease. Newer agents are attempting to address unmet needs in ASCVD
You will learn:
- The consequences of the duration of type 2 diabetes (T2D) in respect of atherosclerotic cardiovascular-related complications
- The role of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in different T2D populations
- The safety profile of GLP-1 RAs.
To access this module, please register or login:
Disclaimer: please note that the content of this report and video is for prescribers
